Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed primary adenocarcinoma of the breast * Locally recurrent or metastatic disease * Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin®) or have previously received trastuzumab in the past * Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm by conventional techniques or as \> 10 mm by spiral CT scan. * No known CNS disease * Hormone receptor status not specified PATIENT CHARACTERISTICS: Inclusion criteria: * Postmenopausal status not specified * ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% * Life expectancy \> 12 weeks * WBC ≥ 3,000/mcL * Absolute neutrophil count ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Total bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis) * Creatinine ≤ 1.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix Exclusion criteria: * Pre-existing neuropathy ≥ grade 1 * Uncontrolled intercurrent illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Serious, non-healing wound, ulcer, or bone fracture * Psychiatric illness/social situations that would limit compliance with study requirements * Inadequately controlled hypertension (defined as systolic blood pressure \> 150 mm Hg and/or diastolic blood pressure \> 100 mm Hg on antihypertensive medications) * History of hypertensive crisis or hypertensive encephalopathy * New York Heart Association class II-IV congestive heart failure * History of myocardial infarction or unstable angina within the past 6 months * History of stroke or transient ischemic attack within the past 6 months * Significant vascular disease (e.g., aortic aneurysm, aortic dissection) * Symptomatic peripheral vascular disease * Evidence of bleeding diathesis or coagulopathy * Significant traumatic injury within the past 28 days * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months * Proteinuria, as demonstrated by either urine protein:creatinine ratio ≥ 1.0 OR urine dipstick for proteinuria ≥ 2+ * Patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein ≤ 1g * History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from all prior therapy * No prior chemotherapy for locally recurrent or metastatic disease * Prior neoadjuvant or adjuvant chemotherapy allowed * More than 1 week since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device * More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy * More than 4 weeks since prior radiotherapy * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) * At least 1 year since prior taxane regimen * No other concurrent investigational agents * Concurrent anticoagulation allowed, provided the following criteria are met: * Stable dose of warfarin or low molecular weight heparin * INR within desired range (2-3) * No evidence of active bleeding or coagulopathy * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent radiotherapy, chemotherapy, immunotherapy, or antitumor hormonal therapy